Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer:... Breast Cancer Res Treat (2017) 165:467–468 DOI 10.1007/s10549-017-4351-0 LETTER TO THE EDITOR Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB? 1 1 1 • • • Vasileios Askoxylakis David P. Kodack Gino B. Ferraro Rakesh K. Jain Received: 27 May 2017 / Accepted: 19 June 2017 / Published online: 22 June 2017 Springer Science+Business Media, LLC 2017 We read with great interest the findings by Lewis-Phillips incidence of extracranial occurrence, whereas CNS relap- et al. on the preclinical delivery of trastuzumab in brain ses do not appear to be affected. Together, these data metastases [1]. The authors compared directly the uptake of suggest that trastuzumab does not directly cause BM, but radiolabeled trastuzumab in isogenic tumors implanted in fails to prevent recurrence in the brain. the brain or the mammary fat pad (MFP) of immune- The efficacy of trastuzumab against established BM competent mice. Interestingly, nearly equivalent Zr- appears to be limited, in comparison to its efficacy against trastuzumab uptake at both sites was reported. Efficacy extracranial disease. Although retrospective clinical anal- analysis of the murine analog of trastuzumab (muMab yses suggest that trastuzumab may prolong survival http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

Loading next page...
 
/lp/springer_journal/antibody-based-therapies-for-the-treatment-of-brain-metastases-from-122E1sbeZ0
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4351-0
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial